Welcome to the new morningstar.co.uk! Learn more about the changes and how our new features help your investing success.

Vaping Backlash Hits Tobacco Shares

Vaping deaths in the US and a regulatory crackdown have sent shockwaves through the tobacco sector, hitting the shares of Imperial and British American Tobacco

James Gard 26 September, 2019 | 11:40AM

Vaping

Shares in FTSE 100 tobacco giant Imperial Brands (IMB) were down 11% as it warned a US regulatory crackdown on vaping would hurt revenues this year.

Imperial, which makes Gauloises, L&B and Davidoff cigarettes, said sales growth would be 2% this year, half previous estimates, and shares fell 232p to £18.33. They are off around 25% year to date.

Revenue from so-called “Next Generation Products”, including vaping, is still expected to be 50% higher this year than last, but again this is below previous forecasts.

Imperial says the US vaping market has “deteriorated considerably” in the last three months. Fears of a crackdown in US states where vaping-related deaths have occurred mean wholesalers and retailers have stopped ordering e-cigarette products. In some US states, such as Massachusetts, the sale of vaping products has been banned.

The Morningstar View

Morningstar analyst Philip Gorham thinks UK-listed tobacco stocks Imperial and BAT are significantly undervalued even with the US crackdown looming, assigning them each a five-star rating. Both stocks have “wide” moats, meaning they have significant competitive advantages. Imperial made it on to our most recent list of top 20 dividend payer, although a dividend cut means its yield will drop from 9% to 5%.

Gorham thinks regulation of the sector is still in its early stages in the US and could lead to higher taxes. “Trump’s proposal significantly accelerates US regulation and could decimate the category in a few years,” he warns.

Still, not all companies in the sector will be affected by any crackdown and the impact on Imperial will be negligible, Gorham predicts. Although it bought vaping company Blu for $7.1 billion, US vaping revenues account for just 1.5% of Imperial’s global revenue.

He also thinks the vaping controversy may lead companies to focus their efforts back on to higher margin “combustible” products, ie. old-fashioned cigarettes, but warns investors that the US regulatory crackdown will likely spread across the world.

Is Vaping Dangerous?

FTSE 100 tobacco firms Imperial and British American Tobacco (BATS) have been stalwarts of income investors’ portfolios for many years, due to their high cash generation and reliable dividends.

But ESG concerns have intensified in recent years and the sector is now out of favour with many investors. Recent vaping deaths in the US, as well as President Trump’s plans to ban non-tobacco vaping liquids, have not helped sentiment. The planned merger of Marlboro maker Philip Morris and Altria, which has been scrapped this week, is a sign of the challenges faced by a once “safe” investment sector. Analysts argue that regulatory risk now means tobacco can now no longer be considered a defensive sector.

Tobacco makers have pinned their hopes on “next generation” smoking products such as e-cigarettes to sustain their business models, but a sudden backlash against vaping in the US has caught them off guard. This is connected to a rash of deaths connected to vaping in the US, where The Centres for Disease Control and Prevention (CDC) said there are 530 cases of lung injuries associated with e-cigarettes. US Congress has held hearings on vapings in the US this week with a view to passing new laws.

The equivalent body in UK, Public Health England, said the UK vaping market was more tightly regulated than in the US and that vaping is still less dangerous than tobacco smoking. “There is no situation where it would be better for your health to continue smoking rather than switching completely to vaping,” the body said.

 

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

About Author

James Gard  is content editor for Morningstar.co.uk

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites